by James Radke | Feb 15, 2021
Jagdish Khubchandani, PhD, Professor of Public Health at New Mexico State University, discusses why individuals might be hesitant about COVID-19 vaccines. As Dr. Khubchandani explains, the COVID-19 vaccines were developed very quickly relative to most other...
by Peter Ciszewski | Feb 12, 2021
Pasi A. Jänne, MD, PhD, from the Dana-Farber Cancer Institute, discusses the efficacy and safety of mobocertinib in previously treated patients with EGFR exon 20-mutated non–small cell lung cancer (NSCLC). Patients with EGFR-mutant NSCLC make up only about 1-2%...
by Peter Ciszewski | Feb 12, 2021
Lance Leopold, MD, Group Vice President, Immuno-Oncology, at Incyte, discusses retifanlimab, an investigational treatment for squamous cell carcinoma of the anal canal (SCAC). SCAC is a rare cancer in which malignant cells form in the cells that line the anus....
by James Radke | Feb 11, 2021
Jagdish Khubchandani, PhD, Professor of Public Health at New Mexico State University, discusses the results of a study assessing national COVID-19 vaccine hesitancy. Dr. Khubchandani, along with other public health researchers, conducted a study to establish a...
by Peter Ciszewski | Feb 10, 2021
John Cataldo, a 29-year old who was diagnosed with primary hyperoxaluria type 1 (PH1) at age 4, describes what it was like growing up with a rare disease. PH1 is a rare genetic disease in which excessive oxalate production leads to painful and recurrent kidney...
